| REPLIGEN CORP. DL-,01 |
| USA |
| Gesundheit |
| US7599161095 / 870980 |
| RGN (Frankfurt) / RGEN (NASDAQ) |
| FRA:RGN, ETR:RGN, RGN:GR, NASDAQ:RGEN |
| - |
| http://www.repligen.com/ |
|
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflo..
>Volltext.. |
| 9463.85 Mio. EUR |
| 9311.32 Mio. EUR |
| 732.71 Mio. EUR |
| 151.89 Mio. EUR |
| -10.74 Mio. EUR |
| -0.19 EUR |
| 629.6 Mio. EUR |
| 663.04 Mio. EUR |
| 118.11 Mio. EUR |
| 6.88 |
| 17.88% |
| -803.51% |
| - |
| - |
| - |
| - |
| REPLIGEN |
| 18.11.26 |
|
||||
|
||||
|